Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation of recombination adenovirus construction body with deletion E1A code sequence and its use

A technology of recombinant adenovirus and construct, applied in the field of medical genetic engineering, can solve the problems of weak therapeutic effect of tumor cells, missing coding sequence, low mutation rate of p53 gene, etc., and achieve the effect of reliable diagnosis of tumor cells

Inactive Publication Date: 2004-10-06
深圳市天达康基因工程有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Existing inventions at home and abroad all have a common feature, that is, the coding sequence of E1B55kDa is deleted by different methods. The therapeutic effect of tumor cells with p53 gene phenotype is weak, and the mutation rate of p53 gene in some large disease tumors, such as acute leukemia, is very low, which has become a deficiency in the clinical application of ONYX-015 and its related products

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation of recombination adenovirus construction body with deletion E1A code sequence and its use
  • Preparation of recombination adenovirus construction body with deletion E1A code sequence and its use
  • Preparation of recombination adenovirus construction body with deletion E1A code sequence and its use

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0019] Example 1: Using site-directed mutagenesis technique to introduce XbaI restriction site in 376-381nt of pCX1 plasmid.

[0020] pCX1 was purchased from Microbix Biosystem Inc. (Toronato, Ontario, Canada, catalog number: PD-01-03). This plasmid contains the 21-5790nt sequence of human adenovirus type 5. The plasmid structure is shown in Figure 1. Site-directed mutagenesis kit QuikChange TM The Site-Directed Mutagenesis Kit (Strategene, U.S.A.) introduced an XbaI restriction site into 376-381nt of the pCX1 plasmid, that is, mutated TGG AGA to TCT AGA. The specific operation was performed according to the instructions provided by Strategene (Fig. 2).

[0021] The PCR primers used for mutation are:

[0022] Primer 1 = 5'-GGG ACT TTG ACC GTT TAC GTC TAG ACTCGC CCA GGT GTT TT-3' (-358nt to -398nt);

[0023] Primer 2 = 5'-C ACC TGG GCG AGT CTA GAC GTA AAC GGTCAA AGT CCC CGC GGC-3' (-394nt to -352nt) (subscript horizontal line is the mutation site).

[0024] The conditions of ...

example 2

[0026] Example 2: Construction of plasmid pCX1-E1A with deletion of 382-1630nt E1A protein coding sequence.

[0027] The PCR reaction primers are:

[0028] Primer 3=5'-CCG CTC TAG AIA ACT TGC ATG GCG TGTTAA-3' (-382nt to -401nt, the subscript horizontal line is the introduced enzyme cutting site XbaI);

[0029] Primer 4=5'-CCG CTC TAG ATC ATG GTC ATG TCA AACACC-3' (-1630nt to -1610nt, the subscript horizontal line is the introduced enzyme cutting site XbaI);

[0030] Using pCX1 as template, PCR reaction was carried out with primer 3 and primer 4.

[0031] The overall reaction system is 50 μl, including: 5×PCR buffer 10 μl; 50mM MgCl 2 2 μl; 10 mM dNTP 1 μl; 10 μM primer 3 1 μl; 10 μM primer 4 1 μl; pCX1 10 ng; Taq2.5u; add water to 50 μl.

[0032] The reaction conditions were: 95°C for 30 seconds; 25 cycles of 94°C for 30 seconds, 55°C for 1 minute, and 72°C for 1 minute; 72°C for 7 minutes.

[0033] The PCR product is a 1.7Kb fragment, digested with XbaI, separated and pu...

example 3

[0035] Example 3: Construction of a recombinant adenovirus construct deleting the entire coding sequence (382-1630nt) of E1A.

[0036] pBHGE3 was purchased from Microbix Biosystem Inc. (Toronato, Ontario, Canada, catalog number: PD-01-12). This plasmid contains the entire genome sequence of human type 5 adenovirus except the packaging signal (194-358nt). See the attached Figure 4. The 293 cell line is a permanent passage cell line obtained by transforming human embryonic kidney cells with sheared human adenovirus type 5 (Ad 5) DNA, purchased from ATCC (American typical culture collection, ATCC, U.S.A., catalog number: ATCC CRL-1573, published 1972). At the time of acquisition, the passage number of the cells was 32 passages. 293 cells were adherent cells, low triploid, 30% of the cells had 64 chromosomes, and 4.2% of the cells had higher ploidy. Co-transfect 293 cells with pBHGE3 and pCX1-E1A, and homologous recombination occurs in the cells. When pCX1-E1A (20nt-381nt and 16...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A recombinant adenovirus configurator deleted EIA coding sequence in human adenovirus type 5 genom and its application to diagnosing and treating tumor are disclosed. The site-directed mutation, PCR augmentation, enzyme severing, linking, subcloning, transfection, and single-cloning purification of recombinant adenovirus technologies, and the deleted EIA (382-1630 nt) sequence are used to screen the recombinant adenovirus configurator of being unable to express the EIA function protein. It can specifically kill tumor cells, but not normal cells, and has synergestic action to chemicotherapeutic medicines.

Description

1. Technical field [0001] The present invention relates to a construction scheme for point-directed deletion (delete) of the E1A coding sequence in the genome of human adenovirus type 5 (Human adenovirus type 5), and an adenovirus construct obtained through the scheme with functions of tumor treatment and diagnosis, It belongs to the technical field of medical genetic engineering. 2. Background technology [0002] The mortality rate of malignant tumors has become the second leading cause of death after cardiovascular and cerebrovascular diseases in China, and the whole society has a great demand for the diagnosis and treatment of malignant tumors. Chemotherapy, radiotherapy, and surgery, which are currently dominant in clinical treatment, have formed a relatively mature treatment system after years of development and improvement, and have achieved good clinical efficacy. However, these classic treatment methods were established and matured in Before a deep understanding of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K48/00A61P35/00C12N7/01C12N15/31C12N15/86C12Q1/70G01N33/574
Inventor 周剑锋马丁卢运萍王世宣徐钢王世安李震中
Owner 深圳市天达康基因工程有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com